Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration

Pathology International

Volumn 60, Issue 5, 2010, Pages 358-364

  Hosoda, Waki ^a   Takagi, Tadayuki ^a   Mizuno, Nobumasa ^a   Shimizu, Yasuhiro ^a   Sano, Tsuyoshi ^a   Yamao, Kenji ^a   Yatabe, Yasushi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acinar cell carcinoma; Ductal carcinoma; Endocrine tumor; Endoscopic ultrasound guided fine needle aspiration; Pancreas

Indexed keywords

CHROMOGRANIN A; K RAS PROTEIN; NEUROENDOCRINE SPECIFIC PROTEIN; ONCOPROTEIN; PROTEIN CK7; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ARTICLE; ASPIRATION BIOPSY; CELL DIFFERENTIATION; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; ENDOSCOPIC ECHOGRAPHY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

BIOPSY, FINE-NEEDLE; CARCINOMA, ACINAR CELL; CARCINOMA, ISLET CELL; CARCINOMA, PANCREATIC DUCTAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOSONOGRAPHY; HOMEODOMAIN PROTEINS; HUMANS; KERATIN-7; PANCREAS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77951921587     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2010.02527.x     Document Type: Article

References (30)

1. Matsuno S, Egawa S, Fukuyama S et al. Pancreatic cancer registry in Japan: 20 years of experience. Pancreas 2004 28 : 219 230.
2. Heits PU, Komminoth P, Perren A et al. Pancreatic endocrine tumors. In : De Lellis RA, Lloyd RV, Heits PU et al, eds. WHO Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs.
3. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol 2008 103 : 475 483.
4. Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 1998 2 : 472 482.
5. Ferrone CR, Tang LH, Tomlinson J et al. Determining prognosis in patients with pancreatic endocrine neoplasms: Can the WHO classification system be simplified? J Clin Oncol 2007 25 : 5609 5615.
6. Klimstra DS, Heffess CS, Oertel JE, Rosai J. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol 1992 16 : 815 837.
7. Holen KD, Klimstra DS, Hummer A et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 2002 20 : 4673 4678.
8. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M. Acinar cell carcinoma of the pancreas: Clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas 2007 35 : 42 6.
9. Yamao K, Sawaki A, Mizuno N, Shimizu Y, Yatabe Y, Koshikawa T. Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB): Past, present, and future. J Gastroenterol 2005 40 : 1013 1023. (Pubitemid 43055284)
10. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006 8 : 335 341.
11. Skacel M, Ormsby AH, Petras RE, McMahon JT, Henricks WH. Immunohistochemistry in the differential diagnosis of acinar and endocrine pancreatic neoplasms. Appl Immunohistochem Mol Morphol 2000 8 : 203 209.
12. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-KRAS genes. Cell 1988 53 : 549 554.
13. Grunewald K, Lyons J, Frohlich A et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989 43 : 1037 1041.
14. Hruban RH, van Mansfeld AD, Offerhaus GJ et al. KRAS oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993 143 : 545 554.
15. Rozenblum E, Schutte M, Goggins M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997 57 : 1731 1734.
16. Pellegata NS, Sessa F, Renault B et al. KRAS and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994 54 : 1556 1560.
17. Moore PS, Orlandini S, Zamboni G et al. Pancreatic tumours: Molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001 84 : 253 262.
18. Hoorens A, Lemoine NR, McLellan E et al. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol 1993 143 : 685 698.
19. Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Isaacson PG. Gastointestinal Pathology: An Atlas and Text, 3rd edn.
20. Barbareschi M, Roldo C, Zamboni G et al. CDX-2 homeobox gene product expression in neuroendocrine tumors: Its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol 2004 28 : 1169 1176.
21. Hruban RH, Pitman MB, Klimstra DS. Tumors of the Pancreas. AFIP Atlas of Tumor Pathology, 4th edn.
22. Tang WT, Stelter AA, French S et al. Loss of cell-adhesion molecule complexes in solid pseudopapillary tumor of pancreas. Mod Pathol 2007 20 : 509 513.
23. Chetty R, Serra S. Membrane loss and aberrant nuclear localization of E-cadherin are consistent features of solid pseudopapillary tumour of the pancreas. An immunohistochemical study using two antibodies recognizing different domains of the E-cadherin molecule. Histopathology 2008 52 : 325 330.
24. Abraham SC, Klimstra DS, Wilentz RE et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 2002 160 : 1361 1369.
25. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006 354 : 526 528 author reply 526-8.
26. Pääbo S, Irwin DM, Wilson AC. DNA damage promotes jumping between templates during enzymatic amplification. J Biol Chem 1990 265 : 4718 4721.
27. Williams C, Pontén F, Moberg C et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999 155 : 1467 1471.
28. Sakamoto H, Shimizu J, Horio Y et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol 2007 212 : 287 294.
29. Yatabe Y, Koga T, Mitsudomi T et al. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol 2004 203 : 645 652.
30. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin/docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): A randomised phase III trial. Lancet Oncol 2010 11 : 121 128.